pharma news today glp-1 obesity drug updates Lilly orforglipron oral phase 3 weight loss trial GLP-1s and the Unintended Consequences

Human apo-lactoferrin as a physiological mimetic of hypoxia stabilizes hypoxia-inducible factor-1 alpha

This treatment involves injecting a solution directly into areas with unwanted fat, like the thighs or belly

Still missing A public dissolution and release curve

The work ahead will determine how far we can go in translating MGBA science into tangible clinical benefits, but the progress to date already suggests that the gut microbiome may become a cornerstone of precision medicine in neurology

Anyone seeking a regulated medical treatment BPC-157 is not an FDA-approved drug

The IPA/Sermorelin blend is a compounded peptide therapy intended for use under medical supervision only